MyFinsight
Home
Blog
About
Net (decrease)
increase in cash and cash...
-$54,880K
(-162.87%↓ Y/Y)
Maturities of marketable
securities
$40,000K
Stock-based compensation
expense
$1,224K
(26.84%↑ Y/Y)
Accrued expenses and
other current...
$867K
(223.51%↑ Y/Y)
Non-cash operating lease
expense
-$85K
Depreciation expense
$20K
Proceeds from the
exercise of stock options
$84K
Net cash used in
investing activities
-$30,181K
Net cash used in
operating activities
-$22,627K
(-13.25%↓ Y/Y)
Net cash (used in)
provided by financing...
-$2,072K
(-101.93%↓ Y/Y)
Canceled cashflow
$40,000K
Canceled cashflow
$2,196K
Canceled cashflow
$84K
Purchases of marketable
securities
$70,181K
Net loss
-$22,371K
(-3.83%↓ Y/Y)
Prepaid expenses and
other current assets
$1,042K
(77.21%↑ Y/Y)
Payment of deferred
transaction costs and...
$2,156K
(-8.10%↓ Y/Y)
Other non-current
assets
$796K
(183.27%↑ Y/Y)
Net amortization of
premiums and accretion of...
$334K
Accounts payable
-$232K
(-110.36%↓ Y/Y)
Operating lease
liabilities
-$48K
Back
Back
Cash Flow
Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. (KLRS)
source: myfinsight.com